The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

“We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

Since its discovery in 2011, CRISPR-Cas 9 has revolutionized medicine. One of the companies at the forefront of this ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

The researchers have conducted a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique aimed at ...

Globally, people get animal protein mostly from chickens, with pigs and cattle in second and third place. A 2023 report ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

PIC's gene-edited pigs are highly resistant to one of the most harmful viruses affecting pig populations worldwide today.

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from ...

Emma Dimery joined the clinical trial after running out of treatment options. For two years, she's been cancer free.

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and ...